Market capitalization | $19.83m |
Enterprise Value | $-16.58m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 0.27 |
EV/Sales (TTM) EV/Sales | -1.70 |
P/S ratio (TTM) P/S ratio | 2.03 |
P/B ratio (TTM) P/B ratio | 0.28 |
Revenue growth (TTM) Revenue growth | 35.86% |
Revenue (TTM) Revenue | $9.78m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
3 Analysts have issued a Bolt Biotherapeutics Inc forecast:
3 Analysts have issued a Bolt Biotherapeutics Inc forecast:
Sep '24 |
+/-
%
|
||
Revenue | 9.78 9.78 |
36%
36%
|
|
Gross Profit | 7.93 7.93 |
149%
149%
|
|
EBITDA | -70 -70 |
4%
4%
|
EBIT (Operating Income) EBIT | -72 -72 |
7%
7%
|
Net Profit | -65 -65 |
9%
9%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Bolt Biotherapeutics, Inc. is a clinical-stage immuno-oncology company developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company was founded by Edgar G. Engleman on January 22, 2015 and is headquartered in Redwood City, CA.
Head office | United States |
CEO | William Quinn |
Employees | 100 |
Founded | 2015 |
Website | www.boltbio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.